Search Results 1981-1990 of 17027 for monoclonal antibody

1. A Study to Determine Recommended Dose, Regimen and Evaluate the Safety and Preliminary Effectiveness of CC-92480 in Combination With Standard Treatments in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) - Mayo Clinic

   Subject has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin ...

2. Lowering Rejection Risk in Organ Transplants (pkg) - Mayo Clinic News Network

   Among the more than 120,000 Americans waiting for an organ transplant, thousands are told their likelihood of rejection is too high to take the risk.

3. Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis - Mayo Clinic

   * Have a positive anti-nuclear antibody (ANA) test result; ANA titer ≥ 1:80 at screening visit based on central or local laboratory result * Active LN at ...

4. A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer - Mayo Clinic

   Any single agent therapy, and any combination of cytotoxic, endocrine, biological targeted agents, and/or humanized antibodies, scheduled to be administered ...

5. Single arm pilot trial of adaptive therapy (AT) with capecitabine for the treatment of breast cancer - Mayo Clinic

   Prior chemotherapy or use of Antibody Drug Conjugate in the Metastatic setting. Any of the following, because this study involves an agent that has known ...

6. Mayo Clinic Podcast - Dr. Gregory Poland - YouTube - 03 22 2...

   And that baby did have antibodies, low level, but nonetheless antibodies, which suggests that that can be ... of their inability to form antibody. So an ...

7. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04) - Mayo Clinic

   participating in observational studies are eligible. - Have previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a ...

8. Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment - Mayo Clinic

   - Immunoglobulin (Ig) G myeloma (serum monoclonal paraprotein [M-protein] level >= 0.5 gram/deciliter [g/dL] or urine M-protein level >= 200 milligram[mg]/ ...

9. Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma - Mayo Clinic

   Patients with positive hepatitis B core antibody positive require negative polymerase chain reaction (PCR) prior to enrollment. Hepatitis B surface antigen ...

10. Master Protocol to Assess the Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors - Mayo Clinic

    vaccine or NY-ESO-1 targeting antibody - Prior gene therapy using an integrating vector - Previous allogeneic hematopoietic stem cell transplant within the ...